Background: In an earlier monocentric study, we have developed a novel non-invasive test system for the prediction of renal allograft rejection, based on the detection of a specific urine metabolite constellation. To further validate our results in a large real-world patient cohort, we designed a multicentric observational prospective study (PARASOL) including six independent European transplant centers. This article describes the study protocol and characteristics of recruited better patients as subjects. Methods: Within the PARASOL study, urine samples were taken from renal transplant recipients when kidney biopsies were performed. According to the Banff classification, urine samples were assigned to a case group (renal allograft rejection), a control group (normal renal histology), or an additional group (kidney damage other than rejection). Results: Between June 2017 and March 2020, 972 transplant recipients were included in the trial (1,230 urine samples and matched biopsies, respectively). Overall, 237 samples (19.3%) were assigned to the case group, 541 (44.0%) to the control group, and 452 (36.7%) samples to the additional group. About 65.9% were obtained from male patients, the mean age of transplant recipients participating in the study was 53.7 ± 13.8 years. The most frequently used immunosuppressive drugs were tacrolimus (92.8%), mycophenolate mofetil (88.0%), and steroids (79.3%). Antihypertensives and antidiabetics were used in 88.0 and 27.4% of the patients, respectively. Approximately 20.9% of patients showed the presence of circulating donor-specific anti-HLA IgG antibodies at time of biopsy. Most of the samples (51.1%) were collected within the first 6 months after transplantation, 48.0% were protocol biopsies, followed by event-driven (43.6%), and follow-up biopsies (8.5%). Over time the proportion of biopsies classified into the categories Banff 4 (T-cell-mediated rejection [TCMR]) and Banff 1 (normal tissue) decreased whereas Banff 2 (antibody-mediated rejection [ABMR]) and Banff 5I (mild interstitial fibrosis and tubular atrophy) increased to 84.2 and 74.5%, respectively, after 4 years post transplantation. Patients with rejection showed worse kidney function than patients without rejection. Conclusion: The clinical characteristics of subjects recruited indicate a patient cohort typical for routine renal transplantation all over Europe. A typical shift from T-cellular early rejections episodes to later antibody mediated allograft damage over time after renal transplantation further strengthens the usefulness of our cohort for the evaluation of novel biomarkers for allograft damage.

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czechia

Department of Nephrology University Hospital Regensburg Regensburg Germany

Division of Nephrology and Dialysis Department of Medicine 3 Medical University of Vienna Vienna Austria

Faculty of Health Grenoble Alpes University Grenoble France

Institute of Pharmacology Philipps University Marburg Germany

Institute of Pharmacology University of Marburg Marburg Germany

Nephrology Department Fundació Puigvert Instituto de Investigaciones Biomédicas Sant Pau Medicine Department Universitat Autónoma de Barcelona REDinREN Instituto de Investigación Carlos 3 Barcelona Spain

Nephrology Hemodialysis Apheresis and Kidney Transplantation Department Grenoble University Hospital Grenoble France

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czechia

umares AG Regensburg Germany

Vall d'Hebron University Hospital Barcelona Spain

Zobrazit více v PubMed

Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. (2010) 363:1451–62. 10.1056/NEJMra0902927 PubMed DOI

Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. (2021) 385:729–43. 10.1056/NEJMra2014530 PubMed DOI

Chapman JR. Do protocol transplant biopsies improve kidney transplant outcomes? Curr Opin Nephrol Hypertens. (2012) 21:580–6. 10.1097/MNH.0b013e32835903f4 PubMed DOI

Tøndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol. (2012) 7:1591–7. 10.2215/CJN.02150212 PubMed DOI PMC

Lo DJ, Kaplan B, Kirk AD. Biomarkers for kidney transplant rejection. Nat Rev Nephrol. (2014) 10:215–25. 10.1038/nrneph.2013.281 PubMed DOI

Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. (2013) 369:20–31. 10.1056/NEJMoa1215555 PubMed DOI PMC

Banas M, Neumann S, Eiglsperger J, Schiffer E, Putz FJ, Reichelt-Wurm S, et al. Identification of a urine metabolite constellation characteristic for kidney allograft rejection. Metabolomics. (2018) 14:116. 10.1007/s11306-018-1419-8 PubMed DOI PMC

Banas MC, Neumann S, Pagel P, Putz FJ, Krämer BK, Böhmig GA, et al. A urinary metabolite constellation to detect acute rejection in kidney allografts. EBioMedicine. (2019) 48:505–12. 10.1016/j.ebiom.2019.10.007 PubMed DOI PMC

Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, et al. A 2018 Reference guide to the banff classification of renal allograft pathology. Transplantation. (2018) 102:1795–814. 10.1097/TP.0000000000002366 PubMed DOI PMC

Jofré R, López-Gómez JM, Moreno F, Sanz-Guajardo D, Valderrábano F. Changes in quality of life after renal transplantation. Am J Kidney Dis. (1998) 32:93–100. 10.1053/ajkd.1998.v32.pm9669429 PubMed DOI

McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. (2018) 30:127–35. 10.1681/ASN.2018050531 PubMed DOI PMC

Wetmore JB, Collins AJ. Meeting the world's need for maintenance dialysis. J Am Soc Nephrol. (2015) 26:2601–3. 10.1681/ASN.2015060660 PubMed DOI PMC

Vanholder R, Domínguez-Gil B, Busic M, Cortez-Pinto H, Craig JC, Jager KJ, et al. Organ donation and transplantation: a multi-stakeholder call to action. Nat Rev Nephrol. (2021) 17:554–68. 10.1038/s41581-021-00425-3 PubMed DOI PMC

Ojo AO, Morales JM, González-Molina M, Steffick DE, Luan FL, Merion RM, et al. Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant. (2013) 28:213–20. 10.1093/ndt/gfs287 PubMed DOI PMC

Perl J, Zhang J, Gillespie B, Wikström B, Fort J, Hasegawa T et al. Reduced survival and quality of life following return to dialysis after transplant failure: the dialysis outcomes and practice patterns study. Nephrol Dial Transplant. (2012) 27:4464–72. 10.1093/ndt/gfs386 PubMed DOI PMC

Coupel S, Giral-Classe M, Karam G, Morcet JF, Dantal J, Cantarovich D et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. Kidney Int. (2003) 64:674–80. 10.1046/j.1523-1755.2003.00104.x PubMed DOI

Clark S, Kadatz M, Gill J, Gill JS. Access to kidney transplantation after a failed first kidney transplant and associations with patient and allograft survival: an analysis of national data to inform allocation policy. Clin J Am Soc Nephrol. (2019) 14:1228–37. 10.2215/CJN.01530219 PubMed DOI PMC

Heaphy ELG, Poggio ED, Flechner SM, Goldfarb DA, Askar M, Fatica R et al. Risk factors for retransplant kidney recipients: relisting and outcomes from patients' primary transplant. Am J Transplant. (2014) 14:1356–67. 10.1111/ajt.12690 PubMed DOI

Johnston O, Rose CL, Gill JS, Gill JS. Risks and benefits of preemptive second kidney transplantation. Transplantation. (2013) 95:705–10. 10.1097/TP.0b013e31827a938f PubMed DOI

Girerd S, Girerd N, Duarte K, Giral M, Legendre C, Mourad G, et al. Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. Transpl Int. (2018) 31:408–23. 10.1111/tri.13105 PubMed DOI

Wong G, Chua S, Chadban SJ, Clayton P, Pilmore H, Hughes PD, et al. Waiting time between failure of first graft and second kidney transplant and graft and patient survival. Transplantation. (2016) 100:1767–75. 10.1097/TP.0000000000000953 PubMed DOI

Herrero E, Portillo JA, Ballestero R, Correas MÁ, Domínguez M, Ramos E, et al. Experiencia en terceros, cuartos y quintos trasplantes renales y sus complicaciones. Arch Esp Urol. (2017) 70:815–23. PubMed

Beltrán Catalán S, Sancho Calabuig A, Molina P, Vizcaíno Castillo B, Gavela Martínez E, Kanter Berga J, et al. Impact of dialysis modality on morbimortality of kidney transplant recipients after allograft failure. Analysis in the presence of competing events. Nefrologia. (2021) 41:200–9. 10.1016/j.nefro.2020.12.007 PubMed DOI

Noble J, Jouve T, Malvezzi P, Süsal C, Rostaing L. Transplantation of marginal organs: immunological aspects and therapeutic perspectives in kidney transplantation. Front Immunol. (2019) 10:3142. 10.3389/fimmu.2019.03142 PubMed DOI PMC

Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation. (2002) 74:1281–6. 10.1097/00007890-200211150-00014 PubMed DOI

Aubert O, Kamar N, Vernerey D, Viglietti D, Martinez F, Duong-Van-Huyen JP, et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ. (2015) 351. 10.1136/bmj.h3557 PubMed DOI PMC

Sung RS, Guidinger MK, Leichtman AB, Lake C, Metzger RA, Port FK, et al. Impact of the expanded criteria donor allocation system on candidates for and recipients of expanded criteria donor kidneys. Transplantation. (2007) 84:1138–44. 10.1097/01.tp.0000287118.76725.c1 PubMed DOI

Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. (2003) 3(Suppl. 4):114–25. 10.1034/j.1600-6143.3.s4.11.x PubMed DOI

Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. (2004) 4:378–83. 10.1111/j.1600-6143.2004.00332.x PubMed DOI

Gwinner W, Metzger J, Husi H, Marx D. Proteomics for rejection diagnosis in renal transplant patients: Where are we now? World J Transplant. (2016) 6:28–41. 10.5500/wjt.v6.i1.28 PubMed DOI PMC

Macpherson NA, Moscarello MA, Goldberg DM. Aminoaciduria is an earlier index of renal tubular damage than conventional renal disease markers in the gentamicin-rat model of acute renal failure. Clin Invest Med. (1991) 14:101–10. PubMed

Millán O, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B, et al. Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. Br J Clin Pharmacol. (2017) 83:2636–50. 10.1111/bcp.13399 PubMed DOI PMC

Suhre K, Schwartz JE, Sharma VK, Chen Q, Lee JR, Muthukumar T, et al. Urine metabolite profiles predictive of human kidney allograft status. J Am Soc Nephrol. (2016) 27:626–36. 10.1681/ASN.2015010107 PubMed DOI PMC

Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, et al. Cell-Free DNA and active rejection in kidney allografts. J Am Soc Nephrol. (2017) 28:2221–32. 10.1681/ASN.2016091034 PubMed DOI PMC

Blydt-Hansen TD, Sharma A, Gibson IW, Wishart DS, Mandal R, Ho J, et al. Urinary metabolomics for noninvasive detection of antibody-mediated rejection in children after kidney transplantation. Transplantation. (2017) 101:2553–61. 10.1097/TP.0000000000001662 PubMed DOI